Adverum Biotechnologies, Inc.: management transactions · United States · SEC (Form 4)

About Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq market in the United States. The company is focused on ocular gene therapy, with a strategy centered on highly prevalent eye diseases that create substantial unmet medical need. Founded in 2006, Adverum is headquartered in Redwood City, California, in the San Francisco Bay Area biotechnology cluster. Its corporate positioning is built around the idea that gene therapy could become a new standard of care for sight-threatening retinal diseases. ([adverum.com](https://adverum.com/wp-content/uploads/Adverum-Corporate-Overview_2025.pdf?utm_source=openai)) Adverum’s business model is essentially pipeline-driven. The company’s proprietary intravitreal platform is designed to deliver durable therapies through a physician’s office setting, aiming to reduce the burden of frequent repeat injections that are currently common in retinal care. Its lead asset is ixoberogene soroparvovec, or Ixo-vec (formerly ADVM-022), a one-time intravitreal gene therapy candidate being developed for neovascular, or wet, age-related macular degeneration (wet AMD). Management has positioned Ixo-vec as a potential long-acting therapy designed to provide sustained aflibercept expression and reduce the treatment burden associated with standard anti-VEGF regimens. ([adverum.com](https://adverum.com/about-us/?utm_source=openai)) From a competitive standpoint, Adverum operates in a crowded and fast-evolving retinal therapeutics landscape. Standard-of-care anti-VEGF injections remain the commercial benchmark in wet AMD, while multiple biotechnology companies are pursuing longer-duration alternatives, including gene therapy approaches and other sustained-delivery technologies. Adverum’s differentiation lies in its “one-and-done” ambition: if successful, it could offer injection freedom and a structurally different value proposition versus chronic dosing. At the same time, this is a high-risk segment, as clinical efficacy, safety, durability, and regulatory acceptance are all critical gating factors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000155837025002000/ocul-20241231x10k.htm?utm_source=openai)) Recent company milestones have been important. In 2025, Adverum initiated ARTEMIS, its first pivotal Phase 3 trial for Ixo-vec, after reporting prior Phase 2 and long-term follow-up data that the company said supported the program’s potential. In October 2025, Adverum and Eli Lilly announced a transaction under which Lilly agreed to acquire Adverum, adding a major strategic dimension to the investment case. For investors, ADVM should therefore be viewed as a Nasdaq-listed United States biotech story with binary clinical upside, a focused ocular gene-therapy pipeline, and an active M&A overlay. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1501756/000162828025017769/exhibit991_41525pressrelea.htm?utm_source=openai))